Acute Effects of an Oral Fat Load on Skeletal Muscle and Hepatic Insulin Sensitivity (FLAME)
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
The development of type 2 diabetes is based on a combination of insulin resistance and beta cell dysfunction. In the last years, elevated FFA were recognized as a key players in the pathogenesis of insulin resistance and type 2 diabetes.
The study compares the acute effects of an oral lipid bolus on insulin sensitivity and hepatic glucose metabolism in healthy humans.
| Condition | Intervention | Phase |
|---|---|---|
|
Insulin Sensitivity |
Biological: fat orally |
Phase 4 |
| Study Type: | Interventional |
| Study Design: | Allocation: Randomized Intervention Model: Crossover Assignment Masking: Open Label Primary Purpose: Basic Science |
| Official Title: | Acute Effects of an Oral Fat Load on Skeletal Muscle and Hepatic Insulin Sensitivity (FLAME-study) |
- Effect of intervention on whole body insulin sensitivity [ Time Frame: 6 hours ] [ Designated as safety issue: No ]
- Effect of intervention on hepatic insulin sensitivity [ Time Frame: 6 hours ] [ Designated as safety issue: No ]
- Effect of intervention on rates of gluconeogenesis and glycogenolysis [ Time Frame: 6 hours ] [ Designated as safety issue: No ]
| Estimated Enrollment: | 20 |
| Study Start Date: | March 2012 |
| Estimated Study Completion Date: | December 2013 |
| Estimated Primary Completion Date: | July 2013 (Final data collection date for primary outcome measure) |
| Arms | Assigned Interventions |
|---|---|
|
Active Comparator: Palm oil orally
oral fat load
|
Biological: fat orally
Oral ingestion of palm oil or canola oil at timepoint zero
|
|
Active Comparator: Canola oil orally
Oral fat load
|
Biological: fat orally
Oral ingestion of palm oil or canola oil at timepoint zero
|
|
Placebo Comparator: Water orally
oral water administration as control
|
Detailed Description:
A dysregulation of lipid metabolism with increased levels of free fatty acids (FFA) represents one key mechanism in the pathogenesis of insulin resistance, which contributes to the development of type 2 diabetes (T2D). In most cases, dyslipidemia is related to obesity and the metabolic syndrome. Not only skeletal muscle glucose uptake, but also hepatic glucose fluxes are altered in insulin resistant states. In obese and T2D subjects, rates of gluconeogenesis (GNG) are increased, but in obese normoglycemic subjects endogenous glucose production (EGP) remains constant because of downregulation of glycogenolysis (GL). However, in T2D subjects, both GNG and GL are elevated, contributing to fasting and postprandial hyperglycemia. Therefore, elevated GNG rates may represent an early event in the pathophysiology of insulin resistance and T2D.
Preliminary studies of our institute show that intravenous lipid infusion with subsequent elevation of FFA results in increased GNG rates without alteration of EGP in lean, non-diabetic subjects. In another recent study we investigated the effects of an oral fat load on hepatic insulin sensitivity. As expected, we did not find any alterations in EGP; however, rates of GNG and GL have not been assessed.
The aim of this study is to analyze the effects of an oral fat load with transiently elevated levels of circulating lipids on hepatic glucose fluxes, especially GNG and GL, to elucidate the role of dietary fat in the induction of insulin resistance in healthy humans.
In this randomized, controlled cross-over study, effects of oral palm oil and canola oil ingestion will be investigated in young, healthy lean subjects. Hepatic glucose fluxes will be assessed by two independent methods, in vivo magnet resonance spectroscopy (MRS) and the deuterated water/acetaminophen method, which also allows for the determination of glycogen cycling rates. Furthermore, hepatic phosphorus metabolites and liver fat content will be monitored by MRS.
Eligibility| Ages Eligible for Study: | 20 Years to 40 Years |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | Yes |
Inclusion Criteria:
- healthy male and female subjects
- age 20-40
- BMI 20-25 kg/m2
Exclusion Criteria:
- hyperlipidemia
- smoking
- pregnancy
- allergy against paracetamol/palm oil/canola oil
- contraindication for MRI investigations
- anaemia
- taking drugs influencing lipid or glucose metabolism, the immune system or antihypertensive treatment
- M. Meulengracht
- Hepatitis/HIV
- chronic diseases
Contacts and Locations| Germany | |
| German Diabetes Center | Recruiting |
| Düsseldorf, Nordrhein-Westfalen, Germany, 40225 | |
| Contact: Sabine Kahl, M.D. +492113382740 sabine.kahl@ddz.uni-duesseldorf.de | |
| Contact: Bettina Nowotny, M.D. +492113382575 bettina.nowotny@ddz.uni-duesseldorf.de | |
| Principal Investigator: Sabine Kahl, M.D. | |
| Study Director: | Michael Roden, Prof., M.D. | German Diabetes Center |
More Information
No publications provided
| Responsible Party: | Bettina Nowotny, Leader Clinical Research Center, German Diabetes Center |
| ClinicalTrials.gov Identifier: | NCT01736202 History of Changes |
| Other Study ID Numbers: | FLAME |
| Study First Received: | November 26, 2012 |
| Last Updated: | November 26, 2012 |
| Health Authority: | Germany: Ethics Commission Germany: Federal Institute for Drugs and Medical Devices |
Keywords provided by German Diabetes Center:
|
oral fat insulin sensitivity |
Additional relevant MeSH terms:
|
Insulin Resistance Hyperinsulinism Glucose Metabolism Disorders Metabolic Diseases |
Insulin Hypoglycemic Agents Physiological Effects of Drugs Pharmacologic Actions |
ClinicalTrials.gov processed this record on May 16, 2013